Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687550 | 0.81 | MAPT (0.63) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL7660532 | 0.81 | MAPT (0.63) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL13053146 | 0.79 | MAPT (0.59) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL155002 | 0.78 | MAPT (1.00) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1420033 | 0.78 | TP53 (0.81) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL10403126 | 0.75 | NPC1 (0.54) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL9642061 | 0.75 | MAPT (0.84) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2125047 | 0.75 | NPC1 (0.70) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2621291 | 0.75 | MAPT (0.70) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL9147178 | 0.75 | NPC1 (0.70) | MAPTNPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0357061-B1 | Angiogenesis inhibitory agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-06-08 | — | — | EP | claimed |
| US-20030100605-A1 | Methods of treating cancer with angiogenesis inhibitors | GRUPP STEPHAN A (US) | 2003-05-29 | — | — | US | disclosed |
| US-6017954-A | ANGIOGENESIS INHIBITORS FOR TREATING AND PREVENTING ANGIOGENESIS-DEPENDENT TUMORS, ESPECIALLY KAPOSI'S SARCOMA, BREAST CANCER, COLON CANCER | CHILDREN'S MEDICAL CENTER CORP. (US) | 2000-01-25 | — | — | US | disclosed |
| US-5698586-A | ADMINISTERING AN O-SUBSTITUTED FUMAGILLOL | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1997-12-16 | — | — | US | disclosed |
| EP-0359036-B1 | Fumagillol derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-03-26 | — | — | EP | disclosed |
| EP-0682020-A1 | Fumagillol derivatives useful as angiogenesis inhibitors | Takeda Chemical Industries, Ltd. (JP) | 1995-11-15 | — | — | EP | disclosed |
| EP-0357061-B1 | Angiogenesis inhibitory agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5290807-A | Antiinflammatory agents | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| US-5180738-A | Angiogenesis Inhibitors | TAKEDA CHEMICAL INDUSTRIES (JP) | 1993-01-19 | — | — | US | disclosed |
| US-5166172-A | Angiogenesis inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5164410-A | Fumagillol derivatives and pharmaceutical compositions thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-17 | — | — | US | disclosed |
| EP-0359036-A1 | Fumagillol derivatives | Takeda Chemical Industries, Ltd. (JP) | 1990-03-21 | — | — | EP | disclosed |
| EP-0357061-A1 | Angiogenesis inhibitory agent | Takeda Chemical Industries, Ltd. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100605-A1 | Methods of treating cancer with angiogenesis inhibitors | VEGFA, FLT4, HIF1AN | MAPT 4734/4885NPC1 2150/4885RAB9A 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.